Breaking News

WuXi Biologics, WuXi STA Establish WuXi XDC JV

To provide contract development and manufacturing of bioconjugates including antibody-drug conjugates (ADCs).

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

WuXi Biologics and WuXi STA, a subsidiary of WuXi AppTec, established a joint venture company named WuXi XDC to provide contract development and manufacturing of bioconjugates including antibody-drug conjugates (ADCs). Dr. Jimmy (Jincai) Li was appointed as CEO of WuXi XDC.   WuXi Biologics and WuXi STA will make capital contributions of $120 million and $80 million respectively to WuXi XDC. WuXi Biologics will own 60% and WuXi STA, 40%. Accordingly, WuXi XDC will become a non-wholly owned sub...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters